7 August 2024 in Neurology, Neuropsychiatry, Psychosomatics
Multiple sclerosis (MS) is an autoimmune-inflammatory and neurodegenerative disease of the central nervous system. The article analyses the ability of cladribine, which due to its selective lymphotoxic effect on activated cells and central effect on immunomodulation in brain tissue underwent successful clinical trials in 2010, when it was (temporarily) approved in Russia.Objective: to analyse the effect of cladribine tablets in daily practice on the course of MS over 3–4 year observational period after immune reconstitution therapy (IRT) in several neurological clinics from different regions of Russia.Material and methods. We collected data on 235 patients from 12 neurological clinics and regional MS centres who were followed for an average of 3.4 years after starting cladribine treatment.Results. An independent analysis of cases in which cladribine tablets were prescribed showed that the reason for prescribing cladribine was highly active MS (HARS) in 159 (67.7%) patients, rapidly progressive MS (RPMS) in 20 (8.5%), active relapsing-remitting MS – in 50 (21.3%) and secondary progressive MS with exacerbations – in 6 (2.5%). Only 12 (5.1%) of these patients had not previously received disease-modifying therapies (DMTs), i.e. in these cases the drug was the first DMT prescribed. Among patients who had received a second-line DMTs before switching to cladribine, 22 had previously received natalizumab, 5 had received ocrelizumab and only 1 had received fingolimod. Remaining patients (n=195) were switched from first-line DMTs. In all cases, a decrease in the frequency of exacerbations was observed during and after completion of the IRT course. Exacerbations between the first and second course of cladribine were observed in 36 patients (15.3% of all treated patients), including in almost half of the cases those who were switched from natalizumab (17 exacerbations or 47.2% of all exacerbations, that developed between the first and second course of therapy) and in three cases – from ocrelizumab (8.3 % of exacerbations that developed between the first and second course of therapy, or 60 % of all those switched from ocrelizumab to cladribine). After completion of full cladribine treatment during the four-year observation period, exacerbations occurred in 14 patients (6% of all patients included in the analysis), six of which occurred after switching from natalizumab.Conclusion. The results are generally consistent with the results of recently published meta-analyses and reviews, but the high likelihood of exacerbations in patients switched from second-line therapies such as natalizumab and ocrelizumab is noteworthy. Both drugs are prescribed for aggressive types of MS with exacerbations (highly active and rapidly progressive) who had a high frequency of exacerbations and an increase in Expanded Disability Status Scale (EDSS) scores prior to being prescribed these drugs. The switch from natalizumab is usually due to an increased risk of developing progressive multifocal encephalopathy with a high titre of antibodies against the JC-virus and the duration of natal izumab use of more than 2 years. It is likely that the resumption of MS activity after discontinuation of natalizumab is quite pronounced, and replacement with treatment with cladribine in tablet form is not able to completely prevent this. In this respect, such a switch does not appear to be optimal, in contrast to cases where first-line drugs are switched to cladribine.
23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Adherence to therapy largely determines the success of treatment interventions: low levels of adherence are associated with reduced treatment effectiveness. For many chronic diseases, the level of adherence to treatment is about 50% or less, which confirms the relevance of this topic and requires its research. The high costs of treatment, the need for long-term continuous use of drugs and the special socio-economic significance of a disease such as multiple sclerosis (MS) determine the importance of maintaining a high level of adherence to its treatment. An analysis of literature data on the concept of treatment adherence, methods of its definition and influencing factors was carried out, the values of the level of adherence in the treatment of MS, as well as measures to maintain it during the COVID-19 pandemic were considered. Increasing awareness of healthcare professionals about the problem of treatment adherence and ways to improve it helps to improve the efficiency of managing patients with MS. The paper considers the primary stage of the strategy to improve treatment adherence among patients with MS, namely the formation of expanded knowledge of the problem by specialists of a multidisciplinary team involved in the diagnosis and treatment of patients with MS.
23 January 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
OBJECTIVE To study a role of serum neurofilament light chains (sNFL) in assessment of course and progression of multiple sclerosis (MS) in the population of patients with MS in the Tomsk region. MATERIAL AND METHODS The study involved 93 patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) (nRRMS=75, nSPMS=18). The study was carried out in a two-stage design: the first stage was a cross-sectional study for the entire sample; the second stage was a prospective observation with two visits for patients with relapse. sNFL concentration was determined by solid-phase ELISA. RESULTS There was no statistically significant difference between RRMS and SPMS, and relapse and remission groups in terms of sNFL levels. Patients with a MS duration exceeding 14 years had higher rates of sNFL than those with a shorter duration (p=0.02). The subjects of the second study stage showed a decrease in sNFL from 2.05 (1.86; 2.19) pg/ml to 1.92 (1.87; 2.04) pg/ml (p=0.005), and slowdown in sNFL reduction correlated with the severity of cognitive impairment (k=0.52; p<0.05). CONCLUSION Dynamic monitoring of sNFL allows the evaluation of the activity of the disease, as well as making an assumption about the compensatory possibilities of subsequent recovery.
13 May 2022 in Russian neurological Journal
One of the most common symptoms of multiple sclerosis is a cognitive impairment, which becomes severe in the late stage of disease. It is difficult to evaluate the probability of cognitive deficit development and the rate of its progression. Evaluation of neurological status and neuroimaging data in neurodegenerative diseases patients show an inconsistency in the severity of cognitive symptoms. This served as the basis for creating the concept of cognitive reserve, which reflects the brain’s ability to compensate cognitive impairment resulting from damage to brain structures. the term «cognitive reserve» has acquired several «concepts». Despite these concepts are used only for scientific researches, it has a good potential for implementation in clinical practice. This review contains information about the supposed physiological mechanisms of the cognitive reserve, role for preventing of the development of cognitive and motor deficit, methods of cognitive reserve quantitative assessment by clinical and neuroimaging methods, and possible ways of increase.
10 August 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To investigate a disease-modifying drugs (DMD) response in multiple sclerosis (MS) in the Tomsk region population and detect clinical factors associated with the treatment response. Material and methods. A 5-year prospective clinical study included 363 MS patients of the Tomsk region taking DMDs of the «first-line» and «second-line treatments». The response to DMDs therapy and the impact of MS clinical characteristics on response to treatment were assessed. Results. Clinical factors associated with resistance to DMD are male gender, partial reduce of the MS onset symptoms, short period of the first remission, severe neurological impairment, high relapse rate and disease progression rate. Conclusion. Clinical features of MS are crucial factors associated with DMD response and should be used to prescribe DMD. This factor assessment can improve efficacy of the personalized MS treatment.
25 November 2023 in Russian neurological Journal
Neurofilaments are the structural components of neuronal axons, therefore are increasingly used in the diagnosis and course evaluation of neurological diseases. Potential application in multiple sclerosis (MS) is disease diagnosis.The aim of this work was to assess the level of serum neurofilament light chains (sNFL) to analyze the diagnostic value in MS.Material and methods. The study group included patients diagnosed with MS (n = 93), mean age — 38.1 (33.6; 45.9) years, EDSS 4 (2; 5.0) points. 75 patients (80.7%) had a relapsing-remitting course (RRMS), 18 (19.3%) had a secondary progressive course (SPMS). The comparison group (n = 40) consisted of forty age- and sex- matched volunteers. The concentration of sNFL was determined by enzyme-linked immunosorbent assay using a multimodal microplate reader Thermo Scientific Varioskan LUX (The Core Facility “Medical Genomics”, Tomsk NRMC). Statistical processing was carried out in the Statistica 12.0, the Mann-Whitney coefficient and ROC curve were used.Results. The sNFL index in patients was higher than in the control group (2.08 (1.88; 2.23) and 1.96 (1.88; 2.08) pg/ml, p = 0.006). However, statistically significant differences were achieved with more than 5 years of MS duration. Sensitivity and specificity were 67.5% and 61.5%, respectively.Conclusion. The sNFL can`t be considered as an early biomarker in MS, so its use in the primary diagnosis of the disease is not appropriate.